Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Neurotech International ( (AU:NTI) ) is now available.
Neurotech International has received Rare Pediatric Disease Designation from the US FDA for its lead drug candidate, NTI164, aimed at treating Rett syndrome. This designation, alongside the existing Orphan Drug Designation, enhances the company’s regulatory strategy by providing potential benefits such as tax incentives and market exclusivity, reinforcing its commitment to developing innovative therapies for rare neurological disorders.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is known for its broad-spectrum oral cannabinoid drug therapy, NTI164, and has conducted various clinical trials in conditions such as Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome.
Average Trading Volume: 1,007,876
Technical Sentiment Signal: Sell
Current Market Cap: A$19.94M
See more data about NTI stock on TipRanks’ Stock Analysis page.